Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Q3 2024 Earnings Conference Call October 29, 2024 8:30 AM ET

Company Participants

Ji-Yon Yi - Investor Relations
Sujal Patel - Co-Founder and Chief Executive Officer
Parag Mallick - Co-Founder and Chief Scientist
Anna Mowry - Chief Financial Officer

Conference Call Participants

Yuko Oku - Morgan Stanley
Subbu Nambi - Guggenheim Securities
Dan Brennan - TD Cowen

Operator

Good day everyone, and thank you for standing by and welcome to Nautilus Third Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. [Operator Instructions] Please be advised that today's conference is being recorded.

Now, I will pass the call over to Ji-Yon Yi with Investor Relations. Please go ahead.

Ji-Yon Yi

Thank you. Earlier today, Nautilus released financial results for the quarter ended September 30, 2024. If you haven't received this news release or if you'd like to be added to the company's distribution list, please send an e-mail to Investor Relations at nautilus.bio.

Joining me today from Nautilus are Sujal Patel, Co-Founder and CEO; Parag Mallick, Co-Founder and Chief Scientist; and Anna Mowry, Chief Financial Officer.

Before we begin, I'd like to remind you that management will make statements during this call that are forward-looking within the meaning of the federal securities laws. These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated. Additional information regarding these risks and uncertainties appears in the section entitled Forward-Looking Statements in the press release Nautilus issued today.

Except as required by law, Nautilus disclaims any intention or obligation to update or revise any financial or product pipeline projections or other forward-looking statements, whether because of new information, future events or otherwise. This conference call contains time-sensitive information and is accurate only as of the live broadcast, October 29, 2024.

With that, I'll turn the call over to Sujal.

Sujal Patel

Thanks, Ji-Yon, and welcome to everyone joining our Q3, 2024 earnings call.

It is an exciting time to be innovating in the proteomics space. From the recent Nobel Prize announcements to advances in the relationship between proteomics and artificial intelligence, we are seeing an increasing recognition of the role that proteomic analysis will play, in shaping the future of biomedical research in human health.

Our team, energized by both that external momentum, and the opportunity to impact one of the last great frontiers in biology, is performing at a very high level. I have been very pleased to see the team's execution, quality and output, expand in an environment where all of Nautilus resources, are being managed very tightly. That ability to do more with less is a testament to the scrappiness and grit, of our entire team.